Financhill
Buy
66

HALO Quote, Financials, Valuation and Earnings

Last price:
$57.32
Seasonality move :
-2.69%
Day range:
$56.19 - $57.97
52-week range:
$42.01 - $70.51
Dividend yield:
0%
P/E ratio:
15.33x
P/S ratio:
6.84x
P/B ratio:
14.72x
Volume:
1.6M
Avg. volume:
2.6M
1-year change:
8.82%
Market cap:
$7.1B
Revenue:
$1B
EPS (TTM):
$3.76

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HALO
Halozyme Therapeutics
$282.7M $1.20 22.18% 66.18% $65.67
ALLO
Allogene Therapeutics
-- -$0.26 -92.41% -24.29% $8.15
BMY
Bristol-Myers Squibb
$11.4B $1.38 -2.15% 186.59% $57.10
JNJ
Johnson & Johnson
$22.9B $2.68 2.89% 142.56% $169.31
MRK
Merck &
$15.9B $2.04 2.66% 96.96% $101.79
PODD
Insulet
$612.3M $0.93 25.31% -64.13% $336.01
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HALO
Halozyme Therapeutics
$57.63 $65.67 $7.1B 15.33x $0.00 0% 6.84x
ALLO
Allogene Therapeutics
$1.26 $8.15 $275.6M -- $0.00 0% 2,988.01x
BMY
Bristol-Myers Squibb
$48.52 $57.10 $98.7B 18.17x $0.62 5.07% 2.07x
JNJ
Johnson & Johnson
$157.69 $169.31 $379.4B 17.54x $1.30 3.18% 4.28x
MRK
Merck &
$84.02 $101.79 $211B 12.23x $0.81 3.81% 3.34x
PODD
Insulet
$297.40 $336.01 $20.9B 53.49x $0.00 0% 10.01x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HALO
Halozyme Therapeutics
75.76% -0.609 19.18% 7.00x
ALLO
Allogene Therapeutics
-- -0.132 -- 12.46x
BMY
Bristol-Myers Squibb
74.09% 0.148 41.04% 1.10x
JNJ
Johnson & Johnson
40.08% 0.056 13.1% 0.96x
MRK
Merck &
41.89% 0.213 16.34% 0.80x
PODD
Insulet
56.03% 1.967 9.18% 3.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HALO
Halozyme Therapeutics
$216.5M $141.5M 26.13% 137.42% 56.01% $153.3M
ALLO
Allogene Therapeutics
-- -$65.2M -52.73% -52.73% -315927.27% -$53M
BMY
Bristol-Myers Squibb
$8.2B $3.5B 7.93% 32.01% 30.94% $1.7B
JNJ
Johnson & Johnson
$14.5B $6.3B 19.44% 30.18% 63.19% $3.4B
MRK
Merck &
$12.1B $5.9B 21.5% 39.02% 40.03% $1.2B
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M

Halozyme Therapeutics vs. Competitors

  • Which has Higher Returns HALO or ALLO?

    Allogene Therapeutics has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of -295454.55%. Halozyme Therapeutics's return on equity of 137.42% beat Allogene Therapeutics's return on equity of -52.73%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    81.73% $0.93 $2B
    ALLO
    Allogene Therapeutics
    -- -$0.28 $461.4M
  • What do Analysts Say About HALO or ALLO?

    Halozyme Therapeutics has a consensus price target of $65.67, signalling upside risk potential of 13.95%. On the other hand Allogene Therapeutics has an analysts' consensus of $8.15 which suggests that it could grow by 546.83%. Given that Allogene Therapeutics has higher upside potential than Halozyme Therapeutics, analysts believe Allogene Therapeutics is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    ALLO
    Allogene Therapeutics
    8 2 0
  • Is HALO or ALLO More Risky?

    Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Allogene Therapeutics has a beta of 0.308, suggesting its less volatile than the S&P 500 by 69.171%.

  • Which is a Better Dividend Stock HALO or ALLO?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Allogene Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or ALLO?

    Halozyme Therapeutics quarterly revenues are $264.9M, which are larger than Allogene Therapeutics quarterly revenues of $22K. Halozyme Therapeutics's net income of $118.1M is higher than Allogene Therapeutics's net income of -$59.7M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.33x while Allogene Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.84x versus 2,988.01x for Allogene Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.84x 15.33x $264.9M $118.1M
    ALLO
    Allogene Therapeutics
    2,988.01x -- $22K -$59.7M
  • Which has Higher Returns HALO or BMY?

    Bristol-Myers Squibb has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 21.93%. Halozyme Therapeutics's return on equity of 137.42% beat Bristol-Myers Squibb's return on equity of 32.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    81.73% $0.93 $2B
    BMY
    Bristol-Myers Squibb
    72.92% $1.20 $67.2B
  • What do Analysts Say About HALO or BMY?

    Halozyme Therapeutics has a consensus price target of $65.67, signalling upside risk potential of 13.95%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.10 which suggests that it could grow by 17.68%. Given that Bristol-Myers Squibb has higher upside potential than Halozyme Therapeutics, analysts believe Bristol-Myers Squibb is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    BMY
    Bristol-Myers Squibb
    2 18 1
  • Is HALO or BMY More Risky?

    Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.75%.

  • Which is a Better Dividend Stock HALO or BMY?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.07% to investors and pays a quarterly dividend of $0.62 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or BMY?

    Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Halozyme Therapeutics's net income of $118.1M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.33x while Bristol-Myers Squibb's PE ratio is 18.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.84x versus 2.07x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.84x 15.33x $264.9M $118.1M
    BMY
    Bristol-Myers Squibb
    2.07x 18.17x $11.2B $2.5B
  • Which has Higher Returns HALO or JNJ?

    Johnson & Johnson has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 50.24%. Halozyme Therapeutics's return on equity of 137.42% beat Johnson & Johnson's return on equity of 30.18%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    81.73% $0.93 $2B
    JNJ
    Johnson & Johnson
    66.4% $4.54 $130.4B
  • What do Analysts Say About HALO or JNJ?

    Halozyme Therapeutics has a consensus price target of $65.67, signalling upside risk potential of 13.95%. On the other hand Johnson & Johnson has an analysts' consensus of $169.31 which suggests that it could grow by 7.37%. Given that Halozyme Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    JNJ
    Johnson & Johnson
    8 13 0
  • Is HALO or JNJ More Risky?

    Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

  • Which is a Better Dividend Stock HALO or JNJ?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.18% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HALO or JNJ?

    Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Halozyme Therapeutics's net income of $118.1M is lower than Johnson & Johnson's net income of $11B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.33x while Johnson & Johnson's PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.84x versus 4.28x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.84x 15.33x $264.9M $118.1M
    JNJ
    Johnson & Johnson
    4.28x 17.54x $21.9B $11B
  • Which has Higher Returns HALO or MRK?

    Merck & has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 32.71%. Halozyme Therapeutics's return on equity of 137.42% beat Merck &'s return on equity of 39.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    81.73% $0.93 $2B
    MRK
    Merck &
    77.98% $2.01 $83.2B
  • What do Analysts Say About HALO or MRK?

    Halozyme Therapeutics has a consensus price target of $65.67, signalling upside risk potential of 13.95%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 21.15%. Given that Merck & has higher upside potential than Halozyme Therapeutics, analysts believe Merck & is more attractive than Halozyme Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    MRK
    Merck &
    12 11 0
  • Is HALO or MRK More Risky?

    Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

  • Which is a Better Dividend Stock HALO or MRK?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.81% to investors and pays a quarterly dividend of $0.81 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HALO or MRK?

    Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Merck & quarterly revenues of $15.5B. Halozyme Therapeutics's net income of $118.1M is lower than Merck &'s net income of $5.1B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.33x while Merck &'s PE ratio is 12.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.84x versus 3.34x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.84x 15.33x $264.9M $118.1M
    MRK
    Merck &
    3.34x 12.23x $15.5B $5.1B
  • Which has Higher Returns HALO or PODD?

    Insulet has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 6.22%. Halozyme Therapeutics's return on equity of 137.42% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    HALO
    Halozyme Therapeutics
    81.73% $0.93 $2B
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About HALO or PODD?

    Halozyme Therapeutics has a consensus price target of $65.67, signalling upside risk potential of 13.95%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 12.98%. Given that Halozyme Therapeutics has higher upside potential than Insulet, analysts believe Halozyme Therapeutics is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    HALO
    Halozyme Therapeutics
    3 4 0
    PODD
    Insulet
    15 2 0
  • Is HALO or PODD More Risky?

    Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

  • Which is a Better Dividend Stock HALO or PODD?

    Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HALO or PODD?

    Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Insulet quarterly revenues of $569M. Halozyme Therapeutics's net income of $118.1M is higher than Insulet's net income of $35.4M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.33x while Insulet's PE ratio is 53.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.84x versus 10.01x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HALO
    Halozyme Therapeutics
    6.84x 15.33x $264.9M $118.1M
    PODD
    Insulet
    10.01x 53.49x $569M $35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
76
MP alert for Jul 11

MP Materials [MP] is down 0.62% over the past day.

Buy
51
NEGG alert for Jul 11

Newegg Commerce [NEGG] is up 54.02% over the past day.

Buy
76
UAL alert for Jul 11

United Airlines Holdings [UAL] is down 4.29% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock